On the TRAIL to Overcome BRAF-Inhibitor Resistance  by Geserick, Peter et al.
On the TRAIL to Overcome
BRAF-Inhibitor Resistance
Peter Geserick1, Meenhard Herlyn2 and Martin Leverkus1
BRAF inhibition has been an instant, although short-lasting, success in BRAF-
mutated melanoma treatment. Novel data by Berger et al. now suggest that BRAF-
inhibitor-mediated ‘‘priming to death’’ facilitates tumor necrosis factor–related
apoptosis-inducing ligand–mediated apoptosis. We give an overview about the
importance of the crosstalk of extrinsic and mitochondrial apoptotic signaling and
propose other combination therapies that may prevent or overcome secondary
resistance in melanoma.
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In comparison with previous decades,
melanoma therapy has made tremen-
dous progress in the past 10 years. This
breathtaking change began in 2001 with
the identification of BRAF V600 muta-
tions in about half of all melanomas.
Subsequently, the successful develop-
ment of small molecules able to block
signaling by mutated BRAF resulted
in clinical studies that showed clinical
benefit unequivocally in melanoma
patients carrying BRAF mutations
(Chapman et al., 2011). In addition to
the BRAF inhibitors vemurafenib and
later dabrafenib, the MEK (MAPK/ERK
kinase) inhibitor trametinib has now
been approved for use by the Federal
Drug Administration. Indicating the sub-
stantial change in clinical perspective in
the first decade of the 21st century,
objective tumor responses have become
clinical realities, rather than exceptions
for patients with metastatic melanoma.
However, most patients relapse within
months, suggesting that secondary
resistance precludes long-term survival.
Therefore, selection of resistant
melanoma cells during drug treatment,
based on the activation of alternative
signaling pathways, is evident and it
makes understanding and overcoming
secondary resistance with combination
therapies a major focus of dermatoon-
cologists. Currently, combination thera-
pies target both BRAF and overactive
MEK (Flaherty et al., 2012), but other
combination therapies are also envi-
sioned (Uzdensky et al., 2013). One
important hallmark of cancer that
holds promise for overcoming primary
or secondary resistance to treatment is
the breaking of cell death resistance
(Hanahan and Weinberg, 2011). Resis-
tance to RAF inhibitors is thought to be
the result of intratumoral ‘‘selection’’,
and this favors concepts of (a) tumor cell
plasticity beyond genetic changes and
(b) deregulation of metabolic programs
upon BRAF-inhibitor treatment (Haq
et al., 2013; Knight et al., 2013). To
identify additional targets that may lead
to improved combination therapies, a
detailed knowledge of signaling events
in BRAF-inhibitor-treated RAF-mutated
melanomas is important. For example,
counter-regulation of the apoptotic
process by the upregulation of antiapo-
ptotic proteins and deregulation of
intracellular proliferative signaling cas-
cades by the permanent activation of
RAS/RAF/MEK/ERK or PI3K/PTEN/AKT is
well recognized, and it may contribute
to secondary resistance (Wolchok et al.,
2013).
See related article on pg 430 Combined therapies that first (or con-
comitantly) inhibit different oncogenic
pathways or are followed by the activa-
tion of the apoptotic signaling machin-
ery are attractive therapeutic strategies
for metastatic melanoma. Such therapies
may prevent—or delay—the develop-
ment of secondary resistance, with clin-
ical benefit. One such signaling
pathway is the extrinsic or death recep-
tor (DR)-induced cell death pathway.
Extrinsic cell death is activated by extra-
cellular stimuli such as TRAIL (tumor
necrosis factor–related apoptosis-indu-
cing ligand), CD95L, or tumor necrosis
factor (also called death ligands).
Stimulation of these receptors results
in the initiation of an intracellular sig-
naling cascade that triggers apoptosis
(Figure 1). The most critical step during
this process is the autoproteolytic acti-
vation of procaspase-8 within the death-
inducing signaling complex (DISC) that
also contains the adapter molecule
FADD and the receptor-interacting pro-
tein 1 (Geserick et al., 2008). Active
caspase-8 transmits apoptosis either by
direct activation of effector caspase-3 or
by triggering the intrinsic apoptotic cell
death pathway mediated by cleavage of
the BH3-Protein Bid. Bim/tBid hetero-
dimers interact directly with Bax and
promote Bax insertion in the mitochon-
dria and pore formation (Kim et al.,
2009), which results in apoptosome-
dependent capase-9 activation. Active
caspase-9 is another promoter of
caspase-3 activation and apoptotic
cell death, executed by cleavage of
hundreds of protease targets. Each step
in the cell death signaling cascade is
controlled tightly by antiapoptotic
proteins. The cellular FLICE-like inhi-
bitory protein (cFLIP) and the X-linked
inhibitor of apoptosis proteins (XIAPs)
are potent caspase inhibitors, and they
are able to suppress either extrinsic or
intrinsic cell death. cFLIP inhibits active
caspase-8 release from the DISC,
thereby suppressing TRAIL- or CD95L-
induced apoptosis in melanoma
(Geserick et al., 2008). In addition,
suppression of the caspase-3/caspase-9
inhibitor XIAP by mitochondrial smac
or small-molecule smac mimetics
(IAP antagonists) also promotes DR-
mediated cell death (Geserick et al.,
2009).
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As reported in this issue of JID, Berger
et al. (2014) investigated the potential of
BRAF and MEK inhibitors, not only to
suppress cell growth but also the
impact of these compounds to modulate
DR-mediated cell death. This team
from Eberle’s group mechanistically
investigated the role of a pan-BRAF
inhibitor (L-779450) and compared it
with the BRAFV600E inhibitor vemu-
rafenib during TRAIL-induced apoptosis
in melanoma. Prestimulation with
L-779450 resulted in an increased
TRAIL cell death response, which
correlated tightly with the suppression
of extracellular signal–regulated kinase
(ERK) phosphorylation. This observed
decrease in ERK phosphorylation was
accompanied by the upregulation of the
proapoptotic ‘‘BH3-only’’ Bcl-2 protein
Bim, by increased conformationally
active Bax protein, and subsequent
release of smac, cytochrome c, and
apoptosis-inducing factor from mito-
chondria. This led to the activation of
caspase-3, which was mediated either
Clinical Implications
 Recently, rapid progress in melanoma pathobiology has led to guarded
optimism about its ultimate control with pharmacologic agents.
 It has become apparent that long-term remissions from metastatic
melanoma will likely require innovative combinations of therapies.
 Combining BRAF inhibitors with other agents that synergistically target
additional ‘‘hallmarks of skin cancer’’ appears most promising.
 Combination therapies of BRAF inhibitors with death receptor agonists
could be ‘‘worth a try.’’
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Figure 1. The role of RAF-inhibitor-induced signaling for the crosstalk of extrinsic and intrinsic cell death signaling pathway in melanomas. The influence of the
pan-RAF inhibitor (L-779450) and BRAF-specific inhibitor (vemurafenib) for extrinsic and intrinsic cell death pathways is marked in blue color. Consequences of
this treatment are marked in red color. Treatment with the pan-RAF-inhibitor L-779450 inhibits both wild-type and mutant BRAF, whereas vemurafenib
suppresses only BRAFV600E. Treatment with RAF inhibitors results in (a) the upregulation of LC3 (autophagy), and (b) inhibition of extracellular signal–regulated
kinase (ERK) phosphorylation and resulting upregulation of Bim without direct cell death induction (‘‘priming’’ of melanoma cells to death). Activation of tumor
necrosis factor–related apoptosis-inducing ligand (TRAIL) death receptors results in procaspase-8 cleavage, subsequent Bid cleavage, and further activation of Bim.
This is sufficient to ultimately induce cell death by the inhibition of antiapoptotic Bcl-2 proteins, and subsequent Bax, but not Bak activation. This is sufficient for
MOMP, loss of mitochondrial membrane potential (C), and release of cytochrome c and apoptosis-inducing factor. In turn, caspase-9 activation in the apoptosome
complex as well as release of smac that suppresses X-linked inhibitor of apoptosis protein leads to melanoma cell death. Either TRAIL-mediated activation of
caspase-8 or mitochondria-facilitated caspase-9 activation (by Bim-facilitated MOMP) leads to caspase-3 activation and apoptosis execution. The role of the
caspase-8 inhibitor cellular FLICE-like inhibitory protein and the impact of BRAF for the regulation of autophagy needs to be substantiated by further experiments
but represents an intriguing twist of BRAF-inhibitor resistance in melanoma. However, acute interference with RAF signaling seems to modulate the intrinsic
signaling pathway directly, opening a ‘‘window of opportunity’’ to overcome resistance mechanisms by combining BRAF inhibitors with death receptor ligands,
autophagy inhibitors, or other compounds that attack the mitochondria and therefore overcome the ‘‘primed to death’’ status of melanoma cells and effectively kill
them. MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase. ?, indicates currently unknown interactions suggested by Berger et al., (2014).
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by activation of caspase-8 (TRAIL treat-
ment) and/or caspase-9 (after BRAFV600E
inhibition). Importantly, functional rele-
vance was demonstrated, because
knockdown of either Bim, Bax, or smac
rescued the melanoma cells from death,
indicating the indispensable role of the
intrinsic cell death pathway during sen-
sitization for TRAIL-mediated cell death
by BRAF inhibitors (Figure 1, blue-
labeled molecules and processes). The
investigators then went on and studied
an intriguing novel aspect of their
results, namely, regulation of the autop-
hagic machinery. Their data give initial
hints for increased autophagy, as indi-
cated by the upregulation of LC3 protein
and increased autophagic cellular mor-
phology upon BRAF-inhibitor treatment
in BRAF-inhibitor-resistant melanoma
cells. These data indicate that melanoma
cells may signal for increased autophagy
and thereby increased cellular recycling
mechanisms as an explanation for treat-
ment resistance.
The study by Eberle and colleagues
highlights several fascinating insights
relevant to treatment. Their first observa-
tion is the suppression of ERK phospho-
rylation and the resulting upregulation
of Bim that follows inhibition of RAF
signaling. Here, RAF-inhibitor-mediated
Bim activation may ‘‘prime the cells to
death’’. From their study, it becomes
clear that Bim activation may be neces-
sary but not sufficient to eliminate RAF-
inhibitor-treated melanoma cells. Thus,
the mitogen-activated protein kinase
(MAPK) pathway activated by RAF pro-
teins is critical for the regulation of
intrinsic cell death signaling machinery.
The second important finding is that
only combined treatment of a RAF
inhibitor with TRAIL triggers the
activation of Bid and Bim, which then
results in the activation of MOMP and
subsequent cell death. For clinical
investigation, both observations may
have relevance for the treatment of
melanomas. Altogether the study
demonstrates that priming toward cell
death, mediated by the suppression of
MAPK signaling pathways in combina-
tion with activation of TRAIL DRs may
be a feasible strategy to avoid RAF-
inhibitor resistance. However, this study
also raises the critical question: what
additional ‘‘hallmarks of skin cancer’’
could be targeted to increase the effi-
cacy of melanoma treatment? As men-
tioned, activation of caspase-8 within
the DISC is indispensable for caspase-3
cleavage and activation of the mito-
chondrial pathway by TRAIL. In this
context, the negative regulation of cas-
pase-8 by its direct inhibitor cFLIP with
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Figure 2. The TRAIL to overcome BRAF-inhibitor resistance: BRAF inhibitor (vemurafenib), pan-RAF inhibitor (L-779450), and MEK inhibitor carry a high
clinically measurable potential for melanoma therapy. However, all inhibitors induce only low levels of cell death and rather prime the melanoma cells to cell
death. RAF inhibitors suppress cell proliferation substantially but cannot trigger melanoma cell death sufficiently. Without further death stimuli, long-term
stimulation with RAF inhibitors therefore promotes development of secondary resistance by alternative activation of other MAPK signaling pathways such as ARAF,
NRAS, and CRAF. Furthermore, RAF-resistant melanomas circumvent the cell death priming event by the induction of autophagy. Both reactivation of alternative
MAPKs as well as activation of the cellular recycling process of autophagy during RAF-inhibitor treatment can lead to increased melanoma remission. We
speculate that RAF and MEK inhibitors as cell death priming compounds that are rapidly followed by direct cell death stimuli such as TRAIL or BH3-mimetics may
prove to be highly beneficial for melanomas. Melanoma cells that survive such combination therapies may benefit from combination treatment with the
autophagy-inhibitor hydroxychloroquine or with pan-RAF inhibitors that target all MAPK. The overall goal of such therapeutic intervention is to overcome
secondary resistance by strong and rapid elimination of all tumor cells without targeting primary cells, facilitated by the use of tumor-specific targeting of mutant
BRAF. AIF, apoptosis-inducing factor; cFLIP, cellular FLICE-like inhibitory protein; DISC, death-inducing signaling complex; MAPK, mitogen-activated protein
kinase; MEK, MAPK/ERK kinase; RIP1, receptor-interacting protein 1; TRAIL, tumor necrosis factor–related apoptosis-inducing ligand; XIAP, X-linked inhibitor of
apoptosis protein.
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its different isoforms appears to operate
in melanoma (Geserick et al., 2008).
Thus, cFLIP can also block tBid–Bim
interaction and protect from priming
toward cell death, resulting in a lack of
BRAF-inhibitor activity. Further studies
are required to investigate the impact of
cFLIP as a biomarker for sensitivity to
activation of the cell death machinery in
melanoma whenever RAF/MEK inhibi-
tors are used. In respect to the noted
suppression of ERK phosphorylation
during BRAF inhibition, novel inhibitors
farther downstream, which target MEK
or ERK directly, and therefore negatively
regulate Bim, may also be a promising
strategy to prime melanomas toward
cell death. Therefore, compound com-
binations of BRAF and MAPK inhibitors
(for example, trametinib) in combination
with DR agonists may represent a useful
strategy (Wolchok et al., 2013). An
additional possibility that has emerged
over the last 5 years is the direct
inhibition of antiapoptotic proteins of
the Bcl-2 family. So-called BH3-
mimetics that activate cell death
directly by inhibiting Bcl-2 and Bcl-XL
and promoting intrinsic cell death by
activation of Bax/Bak were developed
and introduced recently (Souers et al.,
2013). If Bim is the critical protein
that primes melanoma to TRAIL-
mediated cell death, a number of treat-
ment strategies become attractive:
Compounds that activate the cleavage
of Bid (as ‘‘simulated’’ by activation of
caspase-8 during TRAIL stimulation),
MEK or ERK inhibitors (Morris et al.,
2013), or, more directly, BH3-mimetics
such as ABT199 that activate the
Bax/Bak cell death machinery directly
(Souers et al., 2013) could prove
beneficial as combination treatments.
Finally, the induction of autophagy
was hypothesized in the article by
Eberle’s group as a mechanism of how
melanomas bypass the cell death prim-
ing by RAF inhibitors and circumvent
cell death. This raises the intriguing
possibility that BRAF-resistant melano-
mas may have the ability to activate
protective proautophagic signaling path-
ways. For example, melanoma cells
have high requirements for autophagic
flux (Xie et al., 2013). Thus, they may
undergo apoptosis upon co-treatment
using a BRAF inhibitor in combination
with lysosomotropic agents, such as
the autophagy-inhibitor hydroxychloro-
quine (Figure 2). Taken together, it
appears that the best strategy to target
melanoma cells is with a first therapeu-
tic combination regimen and thereby
prevent secondary resistance. Given
the spectacular progress in the develop-
ment of RAF inhibitors, initial treatment
with more than one small molecule
that inhibits several signaling pathways
operative in melanoma appears to be
the better ‘‘TRAIL to death’’ method. As
most of the recent data about the plas-
ticity of tumor cells indicate, it appears
highly likely that direct elimination of
the tumor cells without allowing time
for modulation of cell surface or intra-
cellular modulation of key signaling
pathways is the key for long-term suc-
cess. Thus, potentially long-term remis-
sions from metastatic melanoma may
require such innovative combination
therapies (Holzel et al., 2013). Undoub-
tedly, further experimental and clinical
studies that investigate primary and
secondary resistance to BRAF inhibi-
tion in tumor cells as such, or in
potential treatment-resistant subpopula-
tions (Roesch et al., 2013), will clarify
whether and what combinations of cell
death agonists, autophagy inhibitors, or
ERK or MEK inhibitors will ultimately
become useful.
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